Compare Appian Corp (APPN) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Appian Corp vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Appian Corp trades at $25.44 (market cap $1.86B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $294.72 (market cap $7.94B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 4.3× Appian Corp's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Appian Corp nearer its low. Which is the better fit depends on your goals.
| APPN | BIO | |
|---|---|---|
Market Cap | $1.86B | $7.94B |
Sector | Technology | Health |
52-Week High | $45.64 | $339.75 |
52-Week Low | $18.72 | $241.71 |
Enterprise Value | $1.95B | $7.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Appian (APPN) trades at $25.36, up 0.48% on the day, with a bullish technical signal from moving averages and a consensus price target of $26.20. The company reported positive net income in 2025 after years of losses, with revenue growing to $726.94M and operating cash flow improving to $62.87M. Recent news highlights focus on AI strategy and enterprise adoption, though the CEO's share sale and negative shareholder equity present mixed signals.
The outlook is cautiously optimistic with revenue growth and cash flow recovery, but risks include high debt levels, negative equity, and intense competition. Analyst sentiment is mixed with a majority Hold rating. The stock offers potential from AI-driven growth but requires monitoring of profitability sustainability and balance sheet health.
BIO trades at $296.11, down 0.39% today, with a bullish technical outlook supported by moving averages and a consensus price target of $305. The company reported $2.58B revenue in 2025 with net income of $759.90M, showing a significant turnaround from prior losses. Recent news highlights Nasdaq compliance restoration and participation in industry events, reinforcing operational stability.
BIO presents a positive investment case with strong analyst support (53.85% buy ratings) and improving profitability, though high P/E of 49.27 and recent earnings misses pose valuation and execution risks. Upside potential exists if the company meets future earnings expectations, but investors should monitor debt levels and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
